Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK) and Tempest Therapeutics (TPST) with bullish sentiments.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Merck & Company (MRK)
In a report released yesterday, Asad Haider from Goldman Sachs maintained a Buy rating on Merck & Company, with a price target of $133.00. The company’s shares closed last Monday at $118.10.
According to TipRanks.com, Haider is a 4-star analyst with an average return of
Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $132.24, a 9.7% upside from current levels. In a report issued on March 19, Scotiabank also maintained a Buy rating on the stock with a $136.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Tempest Therapeutics (TPST)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Tempest Therapeutics today and set a price target of $11.00. The company’s shares closed last Monday at $1.52, close to its 52-week low of $0.70.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
Currently, the analyst consensus on Tempest Therapeutics is a Moderate Buy with an average price target of $11.00.
Read More on MRK:
Disclaimer & DisclosureReport an Issue
- Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says
- Terns Pharmaceuticals downgraded to Hold from Buy at Truist
- Merck announces results from CORALreef AddOn study of enlicitide decanoate
- Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
- Winrevair’s Mixed Phase 2 Signal Leaves Merck’s Risk‑Reward Balanced, Supporting a Hold Rating
